ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0857

Comparison of Clinical and Histopathological Scoring Systems in a Japanese Cohort of Patients with ANCA-Associated Glomerulonephritis Diagnosed by Kidney Biopsy

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Oba, Rina, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Kanzaki, Go, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Sasaki, Takaya, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Haruhara, Kotaro, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Okabe, Masahiro, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Yokote, Shinya, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Shimizu, Akihiro, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Koike, Kentaro, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Hirano, Keita, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Okonogi, Hideo, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Tsuboi, Nobuo, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
  • Yokoo, Takashi, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
Background

Predicting the prognosis of antineutrophil cytoplasmic antibody-associated glomerulonephritis (ANCA-GN), which presents diverse clinical manifestations, is essential for guiding appropriate treatment strategies. Several clinical and histopathological scoring systems have been proposed to estimate kidney outcomes in ANCA-GN. This study aimed to compare the performance of these scoring systems in a Japanese cohort of patients with ANCA-GN.

Methods

We retrospectively analyzed 142 patients with biopsy-proven ANCA-GN from six hospitals in Japan. The primary composite outcome was a combination of end-stage kidney disease and all-cause mortality. We evaluated the predictive performance of three established classification/scoring systems: the Berden classification, the Japanese Clinical Grading System for rapidly progressive glomerulonephritis (RPGN), and the ANCA Renal Risk Score (ARRS). In addition, we externally validated two newer systems: the improved ANCA Kidney Risk Score (AKRiS) and the Percentage of ANCA Crescentic Score (PACS).

Results

During a median follow-up of 2.9 years (interquartile range: 0.2–5.7), 47 composite events occurred. The areas under the receiver operating characteristic curve for predicting the primary outcome were as follows: Berden classification, 0.66 (95% CI: 0.57–0.75); Japanese RPGN Clinical Grade, 0.73 (0.64–0.81); ARRS, 0.82 (0.74–0.89); PACS, 0.77 (0.69–0.86); and AKRiS, 0.87 (0.79–0.94). Stratification by AKRiS risk categories revealed 5-year cumulative event-free survival rates of 89.8%, 52.9%, 27.7%, and 0%, respectively (P < 0.001).

Conclusion

This study provides the first external validation of AKRiS and PACS in a Japanese ANCA-GN cohort. The revised AKRiS demonstrated superior performance in predicting hard outcomes compared to other existing scoring systems.

Digital Object Identifier (DOI)